Philippe F. Backeljauw, MD

Fellowship Program Director, Division of Endocrinology

Clinical Director, Cincinnati Growth Center

Director, Turner Syndrome Center of Cincinnati

Professor, UC Department of Pediatrics

Phone 513-636-8444

Fax 513-636-7486

Email philippe.backeljauw@cchmc.org

Clinical

Pediatric endocrinology; growth disorders; Turner syndrome

Dr. Backeljauw's research has focused on clinical trials evaluating the efficacy and safety of recombinant human IGF-I in patients with growth hormone insensitivity syndrome. These studies have led to the USFDA approval of IGF-I as a treatment for growth failure associated with primary IGF-I deficiency. The studies ended in 2012, and results have been published. He has also been involved in other multicenter studies of IGF-I therapy or combined growth hormone plus IGF-I therapy for idiopathic short stature. In collaboration with Dr. Meilan Rutter, they recently finished a comprehensive study looking at the efficacy and safety of IGF-I therapy in patients with Duchenne muscular dystrophy.

Another area of research for Dr. Backeljauw, during the last five years, is related to activities in the Turner Syndrome Center. We now have conducted several clinical research projects evaluating the cardiovascular pathology, hypertension, attention deficit disorder status, gonadectomy surgery outcomes, and, in particular, vasculopathy prevalence in our large cohort of patients with Turner syndrome.

MD: University of Ghent, Belgium.

Residency: Pediatric and Adolescent Medicine, Cleveland Clinic Foundation Children's Hospital, Cleveland, OH.

Fellowship: Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC.

Certification: Pediatrics, 1992; recertified, 1999, 2007; Pediatric Endocrinology, 1995; recertified, 2003, 2013.

Lawson S, Little I, Urbina E, Khoury P, Backeljauw PF. Vasculopathy in the young Turner syndrome population. Accepted for publication in JCEM, July 2014.

Sisley S, Backeljauw PF. Response to Letter to the Editor: Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic children with short stature. J Pediatr. 2013 Nov; 163(5):1535.

Chen J, Gutmark E, Myalavarapu G, Backeljauw PF, Gutmark-Little I, Gutmark E. J Biomech.  Numerical investigation of mass transport through patient-specific deformed aortae.  2013 Oct 21. pii: S0021-9290(13)00485-5. [Epub ahead of print]

Backeljauw PF, Kuntze J, Frane J, Calikoglu A, Chernausek SD.  The recommended dose for IGF-I therapy does not compromise long-term growth. Letter to the editor.  J  Clin Endocrinol  Metab. July 18, 2013.

Sisley S, Vargas-Trujillo M, Khoury J, Backeljauw PF. Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic children with short stature. J Pediatr. 2013;163(4): 1045-1051.

Backeljauw PF, Chernausek SD, Calikoglu A, Kuntze J, Frane J. Adult height in patients with severe primary IGF-I deficiencyHorm Res Paediatr. 2013;80(1): 47-56.

Prahl Wittberg L, van Wyk S, Mihaescu M, Fuchs, L, Gutmark E, Backeljauw P, Gutmark-Little I. The impact of aortic arch geometry on flow characteristics. American Institute of Aeronautics and Astronautics, 51st AIAA Aerospace Sciences Meeting Proceedings. 2013;1-16.

Gutmark-Little I, Backeljauw P. Cardiac magnetic resonance imaging in Turner syndrome. Clinical Endocrinology. 2013;78, 646–658.

Gutmark-Little I, Hor K, Gottliebson W, Cnota J, Gottliebson WM, Backeljauw PF. Partial anomalous pulmonary venous return is common in Turner syndrome. J Pediatr Endocr and Met. 2012;25 (5-6), 435-440.

Bang P, Ahmed F, Argente J, Backeljauw P, Bettendorf M, Bona G, Coutant R, Rosenfeld RG, Walenkamp MJ, Savage MO. Identification and management of poor response to growth-promoting therapy in children with short stature. Clinical Endocrinology (Oxford). 2012;77, 169-181.